Follow-up study of a pharmacovigilance signal: no evidence of increased risk with risperidone of pituitary tumor with mass effect.

@article{McCarren2012FollowupSO,
  title={Follow-up study of a pharmacovigilance signal: no evidence of increased risk with risperidone of pituitary tumor with mass effect.},
  author={Madeline McCarren and Hong Yan Qiu and Najat Ziyadeh and Rong Jiang and Yu Wang and Andrew T. McAfee},
  journal={Journal of clinical psychopharmacology},
  year={2012},
  volume={32 6},
  pages={743-9}
}
INTRODUCTION Pharmacovigilance studies of spontaneous adverse event report databases are used to raise hypotheses about potential safety events. Such studies have found a disproportionately higher number of pituitary tumor reports for risperidone. Because there is a high prevalence of clinically "silent" pituitary adenomas, any increased workup in… CONTINUE READING